Cost-effectiveness of SSRIs: a European
โ
Alan Stewart
๐
Article
๐
1998
๐
John Wiley and Sons
๐
English
โ 65 KB
๐ 2 views
Background: Evaluating treatments for depression is of great importance given that estimates of lifetime prevalence range up to 20 per cent. The class of antidepressants known as Selective Serotonin Reuptake Inhibitors (SSRIs) has been a major innovation in this area, but has also raised questions a